vs
Apellis Pharmaceuticals, Inc.（APLS）与Porch Group, Inc.（PRCH）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Porch Group, Inc.的1.7倍（$199.9M vs $121.1M），Porch Group, Inc.净利率更高（-3.9% vs -29.5%，领先25.6%），Porch Group, Inc.同比增速更快（100.0% vs -5.9%），过去两年Porch Group, Inc.的营收复合增速更高（26.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Porch Group是一家面向屋主的家居改造服务平台，致力于连接屋主与当地的家居装修承包商。平台不仅提供超过160种家居装修项目的在线预约服务，还涵盖专业建议文章与装修成本指南，帮助屋主便捷规划各类家装工程。
APLS vs PRCH — 直观对比
营收规模更大
APLS
是对方的1.7倍
$121.1M
营收增速更快
PRCH
高出105.9%
-5.9%
净利率更高
PRCH
高出25.6%
-29.5%
两年增速更快
PRCH
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $121.1M |
| 净利润 | $-59.0M | $-4.7M |
| 毛利率 | — | 52.7% |
| 营业利润率 | -25.6% | 34.7% |
| 净利率 | -29.5% | -3.9% |
| 营收同比 | -5.9% | 100.0% |
| 净利润同比 | -62.2% | 2.0% |
| 每股收益（稀释后） | $-0.40 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPRCH
| Q1 26 | — | $121.1M | ||
| Q4 25 | $199.9M | $112.3M | ||
| Q3 25 | $458.6M | $115.1M | ||
| Q2 25 | $178.5M | $107.0M | ||
| Q1 25 | $166.8M | $84.5M | ||
| Q4 24 | $212.5M | $75.3M | ||
| Q3 24 | $196.8M | $77.7M | ||
| Q2 24 | $199.7M | $75.9M |
净利润APLSPRCH
| Q1 26 | — | $-4.7M | ||
| Q4 25 | $-59.0M | $-3.5M | ||
| Q3 25 | $215.7M | $-10.9M | ||
| Q2 25 | $-42.2M | $2.6M | ||
| Q1 25 | $-92.2M | $8.4M | ||
| Q4 24 | $-36.4M | $30.5M | ||
| Q3 24 | $-57.4M | $14.4M | ||
| Q2 24 | $-37.7M | $-64.3M |
毛利率APLSPRCH
| Q1 26 | — | 52.7% | ||
| Q4 25 | — | 99.5% | ||
| Q3 25 | — | 75.6% | ||
| Q2 25 | — | 70.9% | ||
| Q1 25 | — | 77.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 79.4% | ||
| Q2 24 | — | 22.1% |
营业利润率APLSPRCH
| Q1 26 | — | 34.7% | ||
| Q4 25 | -25.6% | 14.7% | ||
| Q3 25 | 48.7% | 14.2% | ||
| Q2 25 | -18.6% | 4.7% | ||
| Q1 25 | -50.0% | -1.5% | ||
| Q4 24 | -12.3% | 33.3% | ||
| Q3 24 | -24.0% | -3.2% | ||
| Q2 24 | -14.7% | -69.2% |
净利率APLSPRCH
| Q1 26 | — | -3.9% | ||
| Q4 25 | -29.5% | -3.1% | ||
| Q3 25 | 47.0% | -9.4% | ||
| Q2 25 | -23.6% | 2.4% | ||
| Q1 25 | -55.3% | 9.9% | ||
| Q4 24 | -17.1% | 40.5% | ||
| Q3 24 | -29.2% | 18.5% | ||
| Q2 24 | -18.9% | -84.8% |
每股收益（稀释后）APLSPRCH
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $-0.40 | $0.00 | ||
| Q3 25 | $1.67 | $-0.10 | ||
| Q2 25 | $-0.33 | $0.00 | ||
| Q1 25 | $-0.74 | $0.07 | ||
| Q4 24 | $-0.30 | $0.34 | ||
| Q3 24 | $-0.46 | $0.12 | ||
| Q2 24 | $-0.30 | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $68.4M |
| 总债务越低越好 | — | $391.3M |
| 股东权益账面价值 | $370.1M | $26.3M |
| 总资产 | $1.1B | $806.6M |
| 负债/权益比越低杠杆越低 | — | 14.87× |
8季度趋势，按日历期对齐
现金及短期投资APLSPRCH
| Q1 26 | — | $68.4M | ||
| Q4 25 | $466.2M | $57.3M | ||
| Q3 25 | $479.2M | $85.0M | ||
| Q2 25 | $370.0M | $79.8M | ||
| Q1 25 | $358.4M | $70.4M | ||
| Q4 24 | $411.3M | $191.7M | ||
| Q3 24 | $396.9M | $238.6M | ||
| Q2 24 | $360.1M | $308.4M |
总债务APLSPRCH
| Q1 26 | — | $391.3M | ||
| Q4 25 | — | $392.8M | ||
| Q3 25 | — | $387.1M | ||
| Q2 25 | — | $394.1M | ||
| Q1 25 | — | $409.2M | ||
| Q4 24 | — | $403.9M | ||
| Q3 24 | — | $399.0M | ||
| Q2 24 | — | $436.8M |
股东权益APLSPRCH
| Q1 26 | — | $26.3M | ||
| Q4 25 | $370.1M | $-24.6M | ||
| Q3 25 | $401.2M | $-27.9M | ||
| Q2 25 | $156.3M | $-29.3M | ||
| Q1 25 | $164.2M | $-52.4M | ||
| Q4 24 | $228.5M | $-43.2M | ||
| Q3 24 | $237.1M | $-77.0M | ||
| Q2 24 | $264.3M | $-101.9M |
总资产APLSPRCH
| Q1 26 | — | $806.6M | ||
| Q4 25 | $1.1B | $797.4M | ||
| Q3 25 | $1.1B | $787.7M | ||
| Q2 25 | $821.4M | $770.7M | ||
| Q1 25 | $807.3M | $802.3M | ||
| Q4 24 | $885.1M | $814.0M | ||
| Q3 24 | $901.9M | $867.3M | ||
| Q2 24 | $904.5M | $876.1M |
负债/权益比APLSPRCH
| Q1 26 | — | 14.87× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSPRCH
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $1.2M | ||
| Q3 25 | $108.5M | $40.8M | ||
| Q2 25 | $4.4M | $35.6M | ||
| Q1 25 | $-53.4M | $-11.2M | ||
| Q4 24 | $19.4M | $-26.6M | ||
| Q3 24 | $34.1M | $12.4M | ||
| Q2 24 | $-8.3M | $-26.0M |
自由现金流APLSPRCH
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $1.1M | ||
| Q3 25 | $108.3M | $40.7M | ||
| Q2 25 | $4.4M | $35.4M | ||
| Q1 25 | $-53.4M | $-11.2M | ||
| Q4 24 | $19.3M | $-26.8M | ||
| Q3 24 | — | $12.2M | ||
| Q2 24 | $-8.4M | $-26.0M |
自由现金流率APLSPRCH
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 1.0% | ||
| Q3 25 | 23.6% | 35.4% | ||
| Q2 25 | 2.5% | 33.0% | ||
| Q1 25 | -32.0% | -13.3% | ||
| Q4 24 | 9.1% | -35.6% | ||
| Q3 24 | — | 15.7% | ||
| Q2 24 | -4.2% | -34.3% |
资本支出强度APLSPRCH
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.1% |
现金转化率APLSPRCH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 13.79× | ||
| Q1 25 | — | -1.33× | ||
| Q4 24 | — | -0.87× | ||
| Q3 24 | — | 0.86× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PRCH
暂无分部数据
